Market cap
$0 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | 183.48 | -98.02 | -68.39 | -- |
| EBIT | 51.80 | 83.96 | 16.56 | -488.70 | -295.44 |
| Net Profit | -47.84 | 59.46 | -570.99 | -468.62 | -274.04 |
| EPS | -46.20 | 78.17 | -127.92 | -348.91 | -215.27 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | Dec-22 | Dec-21 | Dec-20 |
| EBIT-Margin
| -5,759.56 | -2,897.08 | -11,492.74 | -- | -26.39 |
| Net Margin
| -29.73 | -26.50 | -- | -- | -29.73 |
| Return on equity
| 5,208.80 | 2,955.72 | 11,344.34 | 3,945.79 | 336.26 |
| Return on Capital
| 2,039.44 | 1,065.18 | -2,645.29 | 7,996.11 | 767.51 |
| Return on Assets
| -1,430.48 | -898.01 | -823.86 | -917.36 | -2,550.21 |
| Debt to Equity (x)
| -- | -- | -10.37 | -- | -0.72 |
Profitability
ROCE
-2,645.29
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
-2,645.29
|
7,996.11
|
767.51
|
173.61
|
-966.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
11,344.34
--
Profit after tax / Average Net worth * 100
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
11,344.34
|
3,945.79
|
336.26
|
118.28
|
-966.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROA
-823.86
--
Profit after tax / Average Total assets * 100
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
-823.86
|
-917.36
|
-2,550.21
|
-147.63
|
-51.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Margin
-11,492.74
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
-11,492.74
|
--
|
-26.39
|
-5.98
|
-63.23
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Margin
-11,728.58
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
-11,728.58
|
--
|
-29.73
|
-6.91
|
-42.86
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
--
|
-1.00
|
-0.12
|
5.20
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EBIT Growth
-447.10
--
Year on year growth in operating profit (EBIT)
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
-447.10
|
-184.94
|
-289.57
|
41.37
|
14.30
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Net Profit Growth
-71.24
--
Year on year growth in profit after tax
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
-71.24
|
-670.16
|
-294.97
|
7.30
|
62.79
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EPS Growth
-0.21
--
Year on year growth in earnings per share
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
-0.21
|
-4.57
|
-1.59
|
0.38
|
0.63
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-10.37
--
Total debt / Net worth
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
-10.37
|
--
|
-0.72
|
-0.43
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
-3.08
--
(Short term borrowings / Net worth)
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
-3.08
|
--
|
-0.53
|
-0.43
|
-0.14
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.37
--
Current Assets / Current Liabilities and Provisions
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
0.37
|
0.37
|
0.20
|
0.00
|
4.91
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Quick Ratio
0.21
--
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
0.21
|
--
|
0.20
|
0.28
|
4.83
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Interest Coverage
-132.80
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
-132.80
|
--
|
-9.70
|
-22.65
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
23.45
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
23.45
|
--
|
0.03
|
0.80
|
3.32
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Asset Turnover
0.07
--
Sales / Average Total Assets
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
0.07
|
--
|
80.12
|
20.75
|
1.07
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Receivable days
69.38
--
Average Debtors / Sales * 365
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
69.38
|
--
|
1.72
|
2.45
|
19.40
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
1,351.86
--
Average Inventory / Sales * 365
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
1,351.86
|
-8.61
|
-2.65
|
-2.03
|
4.44
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
2,965.72
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
2,965.72
|
2,488.09
|
31.00
|
14.56
|
10.95
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
-1,544.48
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
-1,544.48
|
--
|
-31.94
|
-14.15
|
12.88
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
-0.02
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
-0.02
|
-0.80
|
-6.69
|
-3.02
|
-3.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
-2.56
--
Current share price divided by book value per share in the latest financial year
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
-2.56
|
-54.16
|
-24.21
|
-2.40
|
-7.86
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-0.11
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
Dec-18
|
|---|---|---|---|---|---|
|
Statera Biopharma (STAB)
|
-0.11
|
-2.61
|
-8.23
|
-3.70
|
-1.52
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|